Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · DaTSCAN
DaTSCAN 74 MBq/ml solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-090541 · Präparat HOS-084079
Ioflupane binds to the dopamine transporter. Medicines that bind to the dopamine transporter with high
affinity may therefore interfere with DaTSCAN diagnosis. These include amfetamine, bupropion,
cocaine, codeine, dexamfetamine, methylphenidate, modafinil, and phentermine. Selective serotonin
reuptake inhibitors (SSRIs), such as sertraline, may increase or decrease ioflupane binding to the
dopamine transporter. Serotonin-norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine, may
decrease ioflupane binding to the dopamine transporter especially in patients on higher doses.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ioflupane (HOS-090542) norepinephrine (HOS-090547) bupropion (HOS-086329) codeine (HOS-090544) modafinil (HOS-090546) dopamine (HOS-085948) methylphenidate (HOS-090545) venlafaxine (HOS-086573) cocaine (HOS-090543) phentermine (HOS-087483) serotonin (HOS-085477) sertraline (HOS-086247)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-25T02:00:00Z · SHA-256 f40f7ad424fba21e279058645a7f9123ad356bfb210f5e9a98e718256e3987ab · Passage b61bee0e5f8e9e99224bcb5a4db13e8cfb7d2e33ddbe5e161cf3103ca90bf479 · Zeichen 55–644 im Abschnitt
Wechselwirkungen · Evra
EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch · Abschnitt 4.5 · PDF-Seite 12
HOS-110306 · Präparat HOS-093363
Substances increasing the clearance of CHCs (diminished efficacy of CHCs by enzyme-induction),e.g.:
Barbiturates, bosentan, carbamazepine, phenytoin, primidone, rifampicin, modafinil, and HIV
medications ritonavir, nevirapine and efavirenz; and possibly also felbamate, griseofulvin,
oxcarbazepine, topiramate and products containing the herbal remedy St. John's Wort (hypericum
perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): felbamate (HOS-110308) topiramate (HOS-110310) modafinil (HOS-090546) carbamazepine (HOS-085618) griseofulvin (HOS-091156) efavirenz (HOS-087947) nevirapine (HOS-088064) oxcarbazepine (HOS-110224) ritonavir (HOS-084521) bosentan (HOS-086291) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-22T17:22:00Z · SHA-256 08ee5b4a9562d12725bc2847cb5a881102ab4ddbaaf7c1a2e28b65b78fd2ab5d · Passage fce07ed3919e230e3b4b95a7e6bb5e33dc93093d7123a62b45d6e204078c7c16 · Zeichen 1469–1860 im Abschnitt
Wechselwirkungen · Xyrem
Xyrem 500 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 7
HOS-113663 · Präparat HOS-093953
Modafinil
A drug interaction study in healthy adults demonstrated no pharmacokinetic interactions between
sodium oxybate (single dose of 4.5 g) and modafinil (single dose of 200 mg). Sodium oxybate has
been administered concomitantly with CNS stimulant agents in approximately 80% of patients in
clinical studies in narcolepsy. Whether this affected respiration during the night is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-12T16:47:00Z · SHA-256 458b7a20ee31b89a8296f6c62f1482472a82c1e2139396dca882dd3f5b361fd3 · Passage 0591396b65189c8473709010ee2cc3d71ce6de3b0aaaa8d878a41fb6952dbb4e · Zeichen 2277–2667 im Abschnitt
Wechselwirkungen · Bosulif
Bosulif 100 mg film-coated tablets Bosulif 400 mg film-coated tablets Bosulif 500 mg film-coated tablets Bosulif 50 mg hard capsules Bosulif 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-125449 · Präparat HOS-096073
CYP3A inducers
The concomitant use of bosutinib with strong CYP3A inducers (including, but not limited to
carbamazepine, phenytoin, rifampicin, St. John’s Wort), or moderate CYP3A inducers (including, but
not limited to bosentan, efavirenz, etravirine, modafinil, nafcillin) should be avoided, as a decrease in
bosutinib plasma concentration will occur.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546) carbamazepine (HOS-085618) etravirine (HOS-088088) nafcillin (HOS-125452) efavirenz (HOS-087947) bosentan (HOS-086291) phenytoin (HOS-084531) bosutinib (HOS-109449)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:15:00Z · SHA-256 86c38605c3386630b4591643bb4507bc13ee17f96b594c991ef48865ec55c6c0 · Passage 5eff17dd786f2688840280200337da3a194c1cd6ecd53965868255aba9243558 · Zeichen 1849–2202 im Abschnitt
Wechselwirkungen · Lojuxta
Lojuxta 2 mg hard capsules Lojuxta 5 mg hard capsules Lojuxta 10 mg hard capsules Lojuxta 20 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-127370 · Präparat HOS-096397
Inducers of Medicines that induce CYP3A4 When co-administering CYP3A4 inducers
CYP3A4 would be expected to increase the (i.e. aminoglutethimide, nafcillin,
rate and extent of metabolism of non-nucleoside reverse transcriptase
lomitapide. Consequently, this inhibitors, phenobarbital, rifampicin,
would reduce the effect of carbamazepine, pioglitazone, St John’s
lomitapide. Any impact on efficacy Wort, glucocorticoids, modafinil and
is likely to be variable. phenytoin) with Lojuxta, the possibility of a
drug-drug interaction affecting efficacy
should be considered. It is recommended to
increase the frequency of LDL-C assessment
during such concomitant use and consider
increasing the dose of lomitapide to ensure
maintenance of the desired level of efficacy
if the CYP3A4 inducer is intended for
chronic use.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) aminoglutethimide (HOS-127371) nafcillin (HOS-125452) pioglitazone (HOS-089663) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-25T14:24:00Z · SHA-256 56c36935b5cda4380e359902f1acbc5ec5bb081beeb96ca75e5ad86521fcd98c · Passage 50b645c2aa62dfce0afafbda5ce5ea0a9ce6e474f27e7abad1e68aec4b30839e · Zeichen 5862–7266 im Abschnitt
Wechselwirkungen · Latuda
Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-128670 · Präparat HOS-096607
Coadministration of lurasidone with mild (e.g. armodafinil, amprenavir, aprepitant, prednisone,
rufinamide) or moderate (e.g. bosentan, efavirenz, etravirine, modafinil, nafcillin) inducers of
CYP3A4 would be expected to give a <2-fold reduction in lurasidone exposure during
co-administration and for up to 2 weeks after discontinuation of mild or moderate CYP3A4 inducers.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): armodafinil (HOS-128671) rufinamide (HOS-115232) modafinil (HOS-090546) aprepitant (HOS-112506) etravirine (HOS-088088) nafcillin (HOS-125452) amprenavir (HOS-086183) efavirenz (HOS-087947) bosentan (HOS-086291) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T16:17:00Z · SHA-256 1b4eb934eea6c777e082db5accb51f11c854318bf5d2d82b61249264a6b6a684 · Passage ba79ab260f6eb7e32fe670de16b33447a8f83d1a7ad03837bf3d6c29fa902f42 · Zeichen 3208–3582 im Abschnitt
Wechselwirkungen · Reagila
Reagila 1.5 mg hard capsules Reagila 3 mg hard capsules Reagila 4.5 mg hard capsules Reagila 6 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-129551 · Präparat HOS-096751
CYP3A4 inducers
Co-administration of cariprazine with strong and moderate inducers of CYP3A4 may result in a
significant decrease in total cariprazine exposure, therefore the co-administration of cariprazine and
strong or moderate CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampicin, St.
John’s wort (Hypericum perforatum), bosentan, efavirenz, etravirine, modafinil, nafcillin) is
contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) etravirine (HOS-088088) nafcillin (HOS-125452) efavirenz (HOS-087947) bosentan (HOS-086291) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T14:49:00Z · SHA-256 9d13d908e239f6368505bfcde6e4381ffb6295f6bc6de049f006e4abed967ec2 · Passage 9cba3f62355d6d4ec81f38a7f4cc9199cec8a28285558cc468ea783f13f9712b · Zeichen 2075–2514 im Abschnitt
Wechselwirkungen · Reagila
Reagila 1.5 mg orodispersible tablets Reagila 3 mg orodispersible tablets Reagila 4.5 mg orodispersible tablets Reagila 6 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 24
HOS-129584 · Präparat HOS-096751
CYP3A4 inducers
Co-administration of cariprazine with strong and moderate inducers of CYP3A4 may result in a
significant decrease in total cariprazine exposure, therefore the co-administration of cariprazine and
strong or moderate CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampicin, St.
John’s wort (Hypericum perforatum), bosentan, efavirenz, etravirine, modafinil, nafcillin) is
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) etravirine (HOS-088088) nafcillin (HOS-125452) efavirenz (HOS-087947) bosentan (HOS-086291) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T14:49:00Z · SHA-256 9d13d908e239f6368505bfcde6e4381ffb6295f6bc6de049f006e4abed967ec2 · Passage 16cee91e4db162c6c25f4ad137e4c1a92a1135db759a065f894958aa68b874a1 · Zeichen 2019–2423 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 400 mg film-coated tablets Sovaldi 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-129766 · Präparat HOS-096803
Medicinal products that are strong P-gp inducers in the intestine (carbamazepine, phenobarbital,
phenytoin, rifampicin and St. John’s wort) may significantly decrease sofosbuvir plasma concentration
leading to reduced therapeutic effect of Sovaldi and thus are contraindicated with Sovaldi (see
section 4.3). Medicinal products that are moderate P-gp inducers in the intestine (e.g. modafinil,
oxcarbazepine and rifapentine) may decrease sofosbuvir plasma concentration leading to reduced
therapeutic effect of Sovaldi. Co-administration with such medicinal products is not recommended
with Sovaldi (see section 4.4). Co-administration of Sovaldi with medicinal products that inhibit P-gp
and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma
concentration, thus Sovaldi may be co-administered with P-gp and/or BCRP inhibitors. Sofosbuvir and
GS-331007 are not inhibitors of P-gp and BCRP and thus are not expected to increase exposures of
medicinal products that are substrates of these transporters.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage f0890cc7e05936c62d3d2c7cc128981d568e4b4dd49bd6df59189570ec1ad636 · Zeichen 1009–2049 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 400 mg film-coated tablets Sovaldi 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-129777 · Präparat HOS-096803
Medicinal product by Effects on drug levels. Recommendation concerning co-administration
therapeutic areas Mean ratio (90% with Sovaldi
confidence interval) for
AUC, Cmax, Cmina,b
ANALEPTICS
Modafinil Interaction not studied. Co-administration of Sovaldi with modafinil is
Expected: expected to decrease the concentration of
↓ Sofosbuvir sofosbuvir, leading to reduced therapeutic effect of
↔ GS-331007 Sovaldi. Such co-administration is not
recommended.
(Induction of P-gp)
ANTIARRHYTHMICS
Amiodarone Effect on amiodarone and Coadministration of amiodarone with a sofosbuvir-
sofosbuvir concentrations containing regimen may result in serious
unknown. symptomatic bradycardia.
Use only if no other alternative is available. Close
monitoring is recommended if this medicinal
product is administered with Sovaldi (see
sections 4.4 and 4.8).
ANTICOAGULANTS
Vitamin K antagonists Interaction not studied Close monitoring of INR is recommended with all
vitamin K antagonists. This is due to liver function
changes during treatment with Sovaldi.
ANTICONVULSANTS
Phenobarbital Interaction not studied. Sovaldi is contraindicated with phenobarbital and
Phenytoin Expected: phenytoin (see section 4.3).
↓ Sofosbuvir
↔ GS-331007
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) vitamin K (HOS-091176) amiodarone (HOS-085596) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage 3304897802885f5adda74e3f39f0c0deb0246f3bbc292479afba83b13a25cc3c · Zeichen 3255–5348 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 150 mg coated granules in sachet Sovaldi 200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 39
HOS-129837 · Präparat HOS-096803
Medicinal products that are strong P-gp inducers in the intestine (carbamazepine, phenobarbital,
phenytoin, rifampicin and St. John’s wort) may significantly decrease sofosbuvir plasma concentration
leading to reduced therapeutic effect of Sovaldi and thus are contraindicated with Sovaldi (see
section 4.3). Medicinal products that are moderate P-gp inducers in the intestine (e.g. modafinil,
oxcarbazepine and rifapentine) may decrease sofosbuvir plasma concentration leading to reduced
therapeutic effect of Sovaldi. Co-administration with such medicinal products is not recommended
with Sovaldi (see section 4.4). Co-administration of Sovaldi with medicinal products that inhibit P-gp
and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma
concentration, thus Sovaldi may be co-administered with P-gp and/or BCRP inhibitors. Sofosbuvir and
GS-331007 are not inhibitors of P-gp and BCRP and thus are not expected to increase exposures of
medicinal products that are substrates of these transporters.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage f0890cc7e05936c62d3d2c7cc128981d568e4b4dd49bd6df59189570ec1ad636 · Zeichen 1009–2049 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 150 mg coated granules in sachet Sovaldi 200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 40
HOS-129846 · Präparat HOS-096803
Medicinal product by Effects on drug levels. Recommendation concerning co-administration
therapeutic areas Mean ratio (90% with Sovaldi
confidence interval) for
AUC, Cmax, Cmina,b
ANALEPTICS
Modafinil Interaction not studied. Co-administration of Sovaldi with modafinil is
Expected: expected to decrease the concentration of
↓ Sofosbuvir sofosbuvir, leading to reduced therapeutic effect of
↔ GS-331007 Sovaldi. Such co-administration is not
recommended.
(Induction of P-gp)
ANTIARRHYTHMICS
Amiodarone Effect on amiodarone and Coadministration of amiodarone with a sofosbuvir-
sofosbuvir concentrations containing regimen may result in serious
unknown. symptomatic bradycardia.
Use only if no other alternative is available. Close
monitoring is recommended if this medicinal
product is administered with Sovaldi (see
sections 4.4 and 4.8).
ANTICOAGULANTS
Vitamin K antagonists Interaction not studied Close monitoring of INR is recommended with all
vitamin K antagonists. This is due to liver function
changes during treatment with Sovaldi.
ANTICONVULSANTS
Phenobarbital Interaction not studied. Sovaldi is contraindicated with phenobarbital and
Phenytoin Expected: phenytoin (see section 4.3).
↓ Sofosbuvir
↔ GS-331007
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) vitamin K (HOS-091176) amiodarone (HOS-085596) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage fb39dcdf0ac6985b61e44bd534e5592e30cc04fa4792c0151828a7d7ab972fe8 · Zeichen 3253–5403 im Abschnitt
Wechselwirkungen · Intuniv
Intuniv 1 mg prolonged-release tablets Intuniv 2 mg prolonged-release tablets Intuniv 3 mg prolonged-release tablets Intuniv 4 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-131085 · Präparat HOS-097005
8
Moderate CYP3A4/5 Strong CYP3A4/5 inhibitors CYP3A4 inducers
inhibitors
Crizotinib Indinavir Etravirine
Diltiazem Itraconazole Modafinil
Erythromycin Ketoconazole Nevirapine
Fluconazole Posaconazole Oxcarbazepine
Fosamprenavir Ritonavir Phenobarbital
Imatinib Saquinavir Phenytoin
Verapamil Suboxone Primidone
Grapefruit juice Telaprevir Rifabutin
Telithromycin Rifampicin
St. John’s wort
See section 4.2 for further dosing recommendations
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) phenobarbital (HOS-085617) ketoconazole (HOS-084513) modafinil (HOS-090546) crizotinib (HOS-116818) rifabutin (HOS-086262) etravirine (HOS-088088) grapefruit juice (HOS-088787) imatinib (HOS-110212) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) erythromycin (HOS-084514) nevirapine (HOS-088064) oxcarbazepine (HOS-110224) fosamprenavir (HOS-086182) ritonavir (HOS-084521) phenytoin (HOS-084531) posaconazole (HOS-085622) primidone (HOS-090551) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T16:10:00Z · SHA-256 b225f42374a72478897a7ffe5fe45a28ed820ad0d048d0ca17875afae195379b · Passage 83e1890b9137e3eea77358af69aa1280189cb4e822259f47a5be466cc4048489 · Zeichen 3321–4331 im Abschnitt
Wechselwirkungen · Ibrance
IBRANCE 75 mg hard capsules IBRANCE 100 mg hard capsules IBRANCE 125 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-132439 · Präparat HOS-097230
Coadministration of multiple 400 mg daily doses of modafinil, a moderate CYP3A inducer, with a
single 125 mg IBRANCE dose decreased palbociclib AUCinf and Cmax by 32% and 11%, respectively,
relative to a single 125 mg IBRANCE dose given alone. No dose adjustments are required for
moderate CYP3A inducers (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T16:43:00Z · SHA-256 73a98bcaed2e5b347266ff9f037099270b545348fdf729a2479eedc3e06fd319 · Passage c4e786da789a72b5619452cd40e48cfc9009bb5dfa444de861d30012682c181c · Zeichen 1378–1701 im Abschnitt
Wechselwirkungen · Ibrance
IBRANCE 75 mg film-coated tablets IBRANCE 100 mg film-coated tablets IBRANCE 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-132495 · Präparat HOS-097230
Coadministration of multiple 400 mg daily doses of modafinil, a moderate CYP3A inducer, with a
single 125 mg IBRANCE dose decreased palbociclib AUCinf and Cmax by 32% and 11%, respectively,
relative to a single 125 mg IBRANCE dose given alone. No dose adjustments are required for
moderate CYP3A inducers (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T16:43:00Z · SHA-256 73a98bcaed2e5b347266ff9f037099270b545348fdf729a2479eedc3e06fd319 · Passage c4e786da789a72b5619452cd40e48cfc9009bb5dfa444de861d30012682c181c · Zeichen 1382–1705 im Abschnitt
Wechselwirkungen · Venclyxto
Venclyxto 10 mg film-coated tablets Venclyxto 50 mg film-coated tablets Venclyxto 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-135183 · Präparat HOS-097674
Co-administration of 600 mg once daily rifampicin, a strong CYP3A inducer, for 13 days in 10
healthy subjects decreased venetoclax Cmax by 42% and AUC by 71%. Concomitant use of venetoclax
with strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampicin) or moderate CYP3A
inducers (e.g., bosentan, efavirenz, etravirine, modafinil, nafcillin) should be avoided. Alternative
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546) carbamazepine (HOS-085618) etravirine (HOS-088088) nafcillin (HOS-125452) efavirenz (HOS-087947) bosentan (HOS-086291) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-08T16:48:00Z · SHA-256 f5fb95bdf531b038e04eafc19a968401cedfe2f7ee06f04fa27184a292290e6e · Passage 9c56a03c17fca4866bb1ee2c0643fff693c7770f0413b4a20f4d078a54fd2b32 · Zeichen 2397–2777 im Abschnitt
Wechselwirkungen · Tagrisso
TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-135396 · Präparat HOS-097706
In a clinical pharmacokinetic study in patients, the steady-state AUC of osimertinib was reduced by
78% when co-administered with rifampicin (600 mg daily for 21 days). Similarly, the exposure to
metabolite AZ5104 decreased by 82% for the AUC and 78% for Cmax. It is recommended that
concomitant use of strong CYP3A inducers (e.g. Phenytoin, rifampicin and carbamazepine) with
TAGRISSO should be avoided. Moderate CYP3A4 inducers (e.g. bosentan, efavirenz, etravirine,
modafinil) may also decrease osimertinib exposure and should be used with caution or avoided when
possible. There are no clinical data available to recommend a dose adjustment of TAGRISSO.
Concomitant use of St. John’s Wort is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546) carbamazepine (HOS-085618) etravirine (HOS-088088) efavirenz (HOS-087947) bosentan (HOS-086291) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T16:00:00Z · SHA-256 36d1f10f3b323cac93ed4124915e050ad98541d8f140829a41c0c4e0ad3343cb · Passage 4501e7f0bae544f831193f98f05788db42d4eee8e3bfa2f62b6f4f5a1fe170b3 · Zeichen 884–1614 im Abschnitt
Wechselwirkungen · Epclusa
Epclusa 400 mg/100 mg film-coated tablets Epclusa 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-136121 · Präparat HOS-097846
6
products with Epclusa is contraindicated (see section 4.3). Medicinal products that are moderate
P-gp inducers and/or moderate CYP inducers (e.g. efavirenz, modafinil, oxcarbazepine or rifapentine)
may decrease sofosbuvir or velpatasvir plasma concentration leading to reduced therapeutic effect of
Epclusa. Co-administration with such medicinal products is not recommended with Epclusa (see
section 4.4). Co-administration with medicinal products that inhibit P-gp or BCRP may increase
sofosbuvir or velpatasvir plasma concentrations. Medicinal products that inhibit OATP, CYP2B6,
CYP2C8, or CYP3A4 may increase plasma concentration of velpatasvir. Clinically significant
medicinal product interactions with Epclusa mediated by P-gp, BCRP, OATP, or CYP450 inhibitors
are not expected; Epclusa may be co-administered with P-gp, BCRP, OATP and CYP inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546) rifapentine (HOS-116386) efavirenz (HOS-087947) oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage 904fa254d86a3b1d2f87bd3f541d9ea86fc0eb18f164f596eec4f3f7ee8e755a · Zeichen 1348–2209 im Abschnitt
Wechselwirkungen · Epclusa
Epclusa 200 mg/50 mg coated granules in sachet Epclusa 150 mg/37.5 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 38
HOS-136172 · Präparat HOS-097846
Sofosbuvir and velpatasvir are substrates of drug transporters P-gp and BCRP. Velpatasvir is also a
substrate of drug transporter OATP1B. In vitro, slow metabolic turnover of velpatasvir by CYP2B6,
CYP2C8 and CYP3A4 was observed. Medicinal products that are strong inducers of P-gp and/or
strong inducers of CYP2B6, CYP2C8, or CYP3A4 (e.g. carbamazepine, phenobarbital and phenytoin,
rifampicin, rifabutin and St. John’s wort) may decrease plasma concentrations of sofosbuvir or
velpatasvir leading to reduced therapeutic effect of sofosbuvir/velpatasvir. The use of such medicinal
products with Epclusa is contraindicated (see section 4.3). Medicinal products that are moderate
P-gp inducers and/or moderate CYP inducers (e.g. efavirenz, modafinil, oxcarbazepine or rifapentine)
may decrease sofosbuvir or velpatasvir plasma concentration leading to reduced therapeutic effect of
Epclusa. Co-administration with such medicinal products is not recommended with Epclusa (see
section 4.4). Co-administration with medicinal products that inhibit P-gp or BCRP may increase
sofosbuvir or velpatasvir plasma concentrations. Medicinal products that inhibit OATP, CYP2B6,
CYP2C8, or CYP3A4 may increase plasma concentration of velpatasvir. Clinically significant
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) efavirenz (HOS-087947) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage 9aaf624382664712e09a998d5c3447380f0969e14f809738d5faaf0776064425 · Zeichen 713–1967 im Abschnitt
Wechselwirkungen · Spravato
Spravato 28 mg nasal spray, solution · Abschnitt 4.5 · PDF-Seite 7
HOS-139746 · Präparat HOS-098400
Blood pressure should be closely monitored when Spravato is used concomitantly with
psychostimulants (e.g., amphetamines, methylphenidate, modafinil, armodafinil) or other medicinal
products that may increase blood pressure (e.g., xanthine derivatives, ergometrine, thyroid hormones,
vasopressin, or MAOIs, such as, tranylcypromine, selegiline, phenelzine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): armodafinil (HOS-128671) modafinil (HOS-090546) methylphenidate (HOS-090545) selegiline (HOS-086575) phenelzine (HOS-087875) xanthine (HOS-133925) tranylcypromine (HOS-087876)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-23T12:42:00Z · SHA-256 66d3d2c4bc9c09be85b3106118aac863d6fcc4a754ee8fa4571517590a96c3b9 · Passage 1050deb06d59b85112da84d3622bc98dad1e683a24894a99dda1e27d7fe029d3 · Zeichen 160–517 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.